Bioavailability of Intranasal vs. Rectal Diazepam
There remains an unmet medical need in the out-of-hospital management of seizure emergencies because older…
Certara2013 年 2 月 1 日
Analysis of Level A In Vitro-In Vivo Correlations for an Extended-release Formulation with Limited Bioavailability
A two-stage, numerical deconvolution approach was employed to develop level A in vitro–in vivo correlations…
Certara2013 年 1 月 21 日
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects with Type 2 Diabetes Mellitus
The G-protein-coupled receptor 40 agonist (GPR40) TAK-875 is being developed as an adjunct to diet…
Certara2013 年 1 月 9 日
Absolute Abundance and Function of Intestinal Drug Transporters: A Prerequisite for Fully Mechanistic In Vitro-In Vivo Extrapolation of Oral Drug Absorption
The use of whole body physiological-based pharmacokinetic (PBPK) models linked with in vitro-in vivo extrapolation…
Certara2013 年 1 月 1 日
Simulations to Assess Phase 2 Non-inferiority Trials of Different Doses of Capecitabine in Combination with Docetaxel for Metastatic Breast Cancer
A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free…
Certara2012 年 12 月 26 日
Calculating Urine PK Parameters
Pharmacokinetic analysis normally focuses on systemic exposure to a drug; however, much can be learned…
Certara2012 年 12 月 6 日
Novel Biocompatible Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis
Despite advances in rheumatoid arthritis (RA) treatment, efficacious and safe disease-modifying therapy still represents an…
Certara2012 年 12 月 4 日
What Can We Learn from a Human Mass Balance Study?
Mass balance studies are also called “C-14 studies” or “Absorption, Metabolism, and Excretion (AME) studies”.…
Certara2012 年 11 月 27 日
Bioavailability
Discover bioavailability in pharmacokinetics, its types, the first-pass effect, and calculations. Explore tools for accurate…
Certara2012 年 11 月 4 日
Simulations Using a Drug-disease Modeling Framework and Phase 2 Data Predict Phase 3 Survival Outcome in First-line Non-small Cell Lung Cancer
Simulations were performed for carboplatin/paclitaxel (C/P) plus motesanib or bevacizumab vs. C/P as first-line treatment…
Certara2012 年 11 月 1 日
